Scientists identify over 5000 high-risk cancer gene variants

Am­gen of­fered a glance at plans for its obe­si­ty drug can­di­date Mar­i­Tide dur­ing its fourth-quar­ter earn­ings call, in­clud­ing the ex­ten­sion of an on­go­ing Phase II

Ab­b­Vie’s pso­ri­a­sis drug Skyrizi beat out Am­gen’s Ote­zla in a Phase IV head-to-head ef­fi­ca­cy and safe­ty study test­ing both treat­ments in adult pa­tients with mod­er­ate